Eupraxia Pharmaceuticals EPRX
NASDAQ EPRX
$8.31 +0.10 (+1.16%)
At close: Sep 29, 2026 · 4:00 PM EDT

Eupraxia Pharmaceuticals (EPRX) Receivables - Net (2023 - 2025)

Updated

Eupraxia Pharmaceuticals' Receivables - Net came in at $716,095 for the quarter ended Dec 31, 2025, up 177.5% from $258,074 a year earlier.

Analysis

Eupraxia Pharmaceuticals (EPRX) Receivables - Net (2023 - 2025) Analysis & Trends

  • Going back by year, Receivables - Net was $258,074 in the year ended Dec 31, 2024 (+67.9%) and $153,749 in the year ended Dec 31, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Eupraxia Pharmaceuticals 328.04 Mn 326.44 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 716,095.00
Dec 31, 2024 258,074.00
Dec 31, 2023 153,749.00
API Access

Eupraxia Pharmaceuticals Receivables - Net API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-net&ticker=EPRX&period=max&api_key=YOUR_API_KEY